ADCs in Metastatic Breast Cancer: Breakthroughs, Challenges, and the Future of Targeted Therapy
Description
Understanding Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer with Dr Michelle Li.
ADCs are a breakthrough in targeted chemotherapy for metastatic breast cancer. While ADCs like trastuzumab deruxtecan (T-DXd) offer new hope, challenges like resistance and various side effects still remain, and can therefore limit their clinical use.
In this episode, we sit down with Dr Michelle Li from the Peter MacCallum Cancer Centre to discuss:
- The current landscape of metastatic breast cancer.
- The role of ADCs in the treatment of metastatic breast cancer.
- What makes certain treatment options more effective than others in the context of metastatic disease?
- The future steps in this area of research, including the role of international collaboration.
Tune in for a deep dive into this important research.
Donate to Support Life-Saving Research
Like this episode? Find more Breast Cancer Trials Podcast Episodes here
Follow Breast Cancer Trials on Social Media: Instagram: @breastcancertrials Facebook: Breast Cancer Trials LinkedIn: Breast Cancer Trials X: @BCTrialsANZ
Guest: Dr Michelle Li, Peter MacCallum Cancer Centre in Melbourne.
Thank you for listening! If you found this episode valuable, please share it with your loved ones and help spread awareness about genetic testing for breast cancer.
United States
